Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

Authors
  • Ludwig, Heinz
  • Beksac, Meral
  • Bladé, Joan
  • Cavenagh, Jamie
  • Cavo, Michele
  • Delforge, Michel
  • Dimopoulos, Meletios
  • Drach, Johannes
  • Einsele, Hermann
  • Facon, Thierry
  • Goldschmidt, Hartmut
  • Harousseau, Jean-Luc
  • Hess, Urs
  • Kropff, Martin
  • Leal da Costa, Fernando
  • Louw, Vernon
  • Magen-Nativ, Hila
  • Mendeleeva, Larisa
  • Nahi, Hareth
  • Plesner, Torben
  • And 5 more
Type
Published Article
Journal
The Oncologist
Publisher
Alphamed Press
Publication Date
Jan 01, 2011
Volume
16
Issue
4
Pages
388–403
Identifiers
DOI: 10.1634/theoncologist.2010-0386
PMID: 21441574
Source
Medline
License
Unknown

Abstract

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.

Report this publication

Statistics

Seen <100 times